Quantitative Structure–Activity Relationship Models to Predict Cardiac Adverse Effects
Chemical Research in Toxicology · 2024
DOI: 10.1021/acs.chemrestox.4c00186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Research in Toxicology, 2024. Verfasst von Zhongyu Mou und 6 weiteren Autor:innen. Beteiligte Einrichtung: FDA Center for Drug Evaluation and Research (CDER), Silver Spring, Maryland 20903, United States. Hauptthemen laut MEDLINE: Quantitative Structure-Activity Relationship. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Department of Energy, Oak Ridge Institute for Science and Education.
Abstract (Originalsprache)
Drug-induced cardiotoxicity represents one of the most common causes of attrition of drug candidates in preclinical and clinical development. For this reason, the evaluation of cardiac toxicity is essential during drug development and regulatory review. In the present study, drug-induced postmarket adverse event combinations from the FDA Adverse Event Reporting System were extracted for 2002 drugs using 243 cardiac toxicity-related preferred terms (PTs). These PTs were combined into 12 groups based on their clinical relevance to serve as training sets. The optimal classification scheme was determined using a combination of data sources that included drug labeling information, published literature, clinical study data, and postmarket surveillance data. Two commercial QSAR platforms were used to construct 12 models, including general cardiac toxicity, cardiac ischemia, heart failure, cardiac valve disease, myocardial disease, pericardial disease, structural heart disease, cardiac arrhythmia, Torsades de Pointes, long QT syndrome, atrial fibrillation and ventricular arrhythmia, and cardiac arrest. The cross-validated performance for the new models reached a sensitivity of up to 80% and negative predictivity of up to 80%. These new models covering a wide range of cardiac endpoints will provide fast, reliable, and comprehensive predictions of potential cardiotoxic compounds in drug discovery and regulatory safety assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- FDA Center for Drug Evaluation and Research (CDER), Silver Spring, Maryland 20903, United States.
- Instem, Columbus, Ohio 43215, United States.
- MultiCASE, Inc., Mayfield Heights, Ohio 44124, United States.
ORCID-Profile: Zhongyu Mou, Kevin P Cross, Lidiya Stavitskaya
Förderung
- U.S. Department of Energy
- Oak Ridge Institute for Science and Education
Zitieren
APA
Mou, Z., Volarath, P., Racz, R., Cross, K. P., Girireddy, M., Chakravarti, S., & Stavitskaya, L. (2024). Quantitative Structure–Activity Relationship Models to Predict Cardiac Adverse Effects. Chemical Research in Toxicology. https://doi.org/10.1021/acs.chemrestox.4c00186
Vancouver
Mou Z, Volarath P, Racz R, Cross KP, Girireddy M, Chakravarti S, et al. Quantitative Structure–Activity Relationship Models to Predict Cardiac Adverse Effects. Chemical Research in Toxicology. 2024. doi:10.1021/acs.chemrestox.4c00186
BibTeX
@article{Mou2024,
author = {Mou, Zhongyu and Volarath, Patra and Racz, Rebecca and Cross, Kevin P and Girireddy, Mounika and Chakravarti, Suman and Stavitskaya, Lidiya},
title = {Quantitative Structure–Activity Relationship Models to Predict Cardiac Adverse Effects},
journal = {Chemical Research in Toxicology},
year = {2024},
doi = {10.1021/acs.chemrestox.4c00186}
}
EUVIMED